纵横研报
Ticker Detail

301301.SHE

¥8.76+2.22% 川宁生物 Biotechnology
00Reports China 医疗健康
Yili Chuanning Biotechnology Co. Ltd. A
医疗健康 · 生物科技

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. It offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxycholic acid; coenzyme Q10 mycelia; and other products. It also provides synthetic biology products, including bisabolol, 5-hydroxytryptophan, ergothioneine, ectoine, inositol, squalane, polyhydroxyalkanoate (PHA), and phytosphingosine. In addition, the company engages in trading, crop cultivation, detection, technical consultation, and asset investment activities. The company was incorporated in 2010 and is based in Yining, China. Yili Chuanning Biotechnology Co.,Ltd. operates as a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.

MARKET 市值 18.82B CNY PE 32.4x 52W ¥7.69 – ¥12.71 EODHD · Q 2026-03-31 · 同步 2026-07-12
QUALITY PEG 营收 YoY -15.6% ROE 7.2% 营业利润率 14.1% 净利润率 13.4%
ANALYST 股息率 2.11%

暂无相关研报

数据库中已收录该标的的基本面数据,可发起一份定制研报。

CUSTOM RESEARCH · 定制研报 没找到完全契合的标的?让我们替你做一份。 告诉我们你关心的标的与偏好,1 个工作日内在站内上线。 开始定制